Previous 10 | Next 10 |
2024-02-10 02:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the Guggenheim 6 th Annual Biotechnology Conference in New York, New York on We...
2024-01-18 07:55:57 ET More on HilleVax Seeking Alpha’s Quant Rating on HilleVax Historical earnings data for HilleVax Financial information for HilleVax For further details see: HilleVax appoints McLoughlin as COO
BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of Sean McLoughlin as Chief Operating Officer. As part of a planned transition in connectio...
2024-01-14 03:40:00 ET Summary Shanghai Argo Biopharma entered two agreements with Novartis for a total value of $4.2 billion. San Diego’s Ambrx Biopharma will be acquired by Johnson & Johnson for $2 billion. GSK plans to acquire Aiolos Bio, a San Francisco-London s...
BOSTON and CHENGDU, China, Jan. 08, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, and Chengdu Kanghua Biological Products Co., Ltd. (Kangh) (SHE: 300841), a biopharmaceutical company eng...
BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco, California...
2023-12-12 21:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-10 07:14:34 ET More on HilleVax HilleVax: Takeda's Norovirus Vaccine Spinout Seeking Alpha’s Quant Rating on HilleVax Historical earnings data for HilleVax Financial information for HilleVax For further details see: HilleVax GAAP EP...
BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended September 30, 2023, highlighted recent progress and outlined key upc...
News, Short Squeeze, Breakout and More Instantly...
HilleVax Inc. Company Name:
HLVX Stock Symbol:
NASDAQ Market:
Shares of Core & Main Inc (NYSE:CNM) fell sharply during Tuesday's session after the company reported mixed first-quarter financial result...
U.S. stocks were mixed, with the Dow Jones index gaining around 20 points on Tuesday. Shares of Saia Inc (NASDAQ:SAIA) rose sharply during today...
2024-05-31 14:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...